NEEDHAM, Mass., May 6, 2024 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that Reenie McCarthy, Stealth’s Chief Executive Officer, will participate in a fireside chat at the JMP Citizens Life Sciences Conference in New York on Monday, May 13 at 2:30 p.m. ET and participate in 1×1 meetings with investors.
A live webcast of the presentation will be available here. A replay of the webcast will be available for a limited time following the presentation.
About Stealth Biotherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for age-related and rare genetic diseases involving mitochondrial dysfunction. The Company is initiating Phase 3 clinical trials of elamipretide, its lead investigational product candidate, in dry age-related macular degeneration. Elamipretide is also being tested in a fully enrolled Phase 3 clinical trial in primary mitochondrial myopathy, a rare skeletal myopathic disease, and is under review by the Food and Drug Administration for Barth syndrome, an ultra-rare cardioskeletal disease. The Company is developing its second-generation clinical-stage candidate, bevemipretide (SBT-272), for ophthalmic and neurological disease indications. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates.
Investor Relations Contact
Austin Murtagh
Stern Investor Relations Austin.Murtagh@sternir.com
Media Contact
Anna Stallmann
Anna Stallmann Communications Anna@annacomms.com
SOURCE Stealth BioTherapeutics Inc.
